Journal
CANCER DISCOVERY
Volume 10, Issue 8, Pages 1121-1128Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-20-0596
Keywords
-
Categories
Funding
- Memorial Sloan Kettering Cancer Center [P30-CA008748]
- Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center
- Ludwig Collaborative, Memorial Sloan Kettering Cancer Center
- Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center
- NIH [T32-CA009207, K30-UL1TR00457]
- Damon Runyon Cancer Research Foundation [CI-98-18]
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) pandemic has led to dramatic changes in oncology practice. It is currently unknown whether programmed death 1 (PD-1) blockade therapy affects severity of illness from COVID-19 in patients with cancer. To address this uncertainty, we examined consecutive patients with lung cancers who were diagnosed with COVID-19 and examined severity on the basis of no or prior receipt of PD-1 blockade. Overall, the severity of COVID-19 in patients with lung cancer was high, including need for hospitalization in more than half of patients and death in nearly a quarter. Prior PD-1 blockade was, as expected, associated with smoking status. After adjustment for smoking status, PD-1 blockade exposure was not associated with increased risk of severity of COVID-19. PD-1 blockade does not appear to affect the severity of COVID-19 in patients with lung cancers. SIGNIFICANCE: A key question in oncology practice amidst the COVID-19 pandemic is whether PD-1 blockade therapy affects COVID-19 severity. Our analysis of patients with lung cancers supports the safety of PD-1 blockade treatment to achieve optimal cancer outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available